In this issue:
2021 EMN review and consensus statement on smoldering MM
MAIA: Daratumumab front-line regimen new standard for transplant-ineligible disease
Real-world effectiveness of KCd triplet for triple-class refractory MM
Sustained clinical activity of single-agent belamaf in heavily pre-treated RRMM
VRD consolidation therapy for newly diagnosed disease improves PFS
Recombinant human thrombopoietin accelerates platelet engraftment after ASCT
Could miRNAs be biomarkers of chemotherapy-induced peripheral neuropathy?
The EMN recommends COVID vaccination for all patients with MM
Utilising gene therapy techniques to target KRAS mutants in MM
Cereblon enhancer methylation a mechanism of IMiD resistance in MM
Please login below to download this issue (PDF)